Serum Inst of India to Invest in SEZ
India's largest exporter of vaccines and immuno-biologicals, Serum Institute of India, is to invest 120.0 million rupees ($2.7 million) in the country's Special Economic Zone in Pune, Mumbai, focusing on biotechnology and pharmaceutical products.
In an interview, chief executive Cyrus Poonawaala, said: "Serum Institute will have five to six units in the SEZ, with production commencing by the end of this year. The new units would make vaccines for pneumonia, rotavirus and combination vaccines for the entire range of meningitis, influenza and HIV."
He added that oncology products for the US and European Union markets are also expected to be produced in plants prequalified by the World Health Organization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze